DelveInsight Portfolio Reached 3000+ Reports in Less Than One Year

DelveInsight has released 3000+ Reports in market based on indication, MOA, API, drug, Gene Therapy, Anticoagulants, ADC and PD-1 and PDL-1.

Delhi, India, April 23, 2015 –(PR.com)– DelveInsight Market Research (“DelveInsight”), a leading Market Research and Business Consultant firm mainly focused on making strategic Reports, competitive intelligence and consulting projects, today announced that it has launched 3000+ Reports in less than one year.

DelveInsight has started its Delhi Business operations in 2014 and within the span of one year; company has become one of the Top leaders in making strategic decisions for the Pharmaceuticals Companies.

Dr. B.K Agrawal, Founder and Managing Partner of DelveInsight, said, “We are proud to have been part of building the premier brand and platform driven by an exceptionally strong and motivated management team to provide a one stop solution to support our clients. We wish the DelveInsight team continued success in delivering on this potential.”

DelveInsight has established its strong presence in therapeutic areas and has launched Analytical Reports on Indication, Mechanism of Actions, Drugs, Global API Manufacturers and Specialized Reports on Gene Therapy, Anticoagulants, PD-1 and PDL-1 and Antibody Drug conjugates. The company is further planning to release analytical reports on upcoming researched areas.

For more about the DelveInsight, visit www.delveinsight.com and www.delveinsightblog.wordpress.com

For more information on Reports and Consulting Projects, mail at info@delveinsight.com
Contact Information
DelveInsight
Mridhu Verma
+91-11-4568 9769
Contact
www.delveinsight.com